Physician profile
Leigh Gray
NPI 1043326929
$2,109.64
in general payments reported to CMS, 2019-2025
24 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $221 · 2021: $462 · 2022: $330 · 2023: $388 · 2024: $242 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.41 | 2020-2023 | |
| Amgen INC. | $406.49 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $199.61 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.16 | 2019-2022 | |
| Astellas Pharma US INC | $110.60 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $85.89 | 2019-2025 | Novasure, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $79.11 | 2024-2025 | Slynd |
| Mayne Pharma Commercial LLC | $71.42 | 2024-2025 | |
| Medtronic, INC. | $66.13 | 2023-2024 | Sonicision, Resparray |
| Organon LLC | $61.56 | 2021-2024 | Nexplanon |
| Shield Therapeutics INC | $61.09 | 2022-2024 | Accrufer |
| Daiichi Sankyo INC. | $46.53 | 2021 | |
| Sumitomo Pharma America, INC. | $46.50 | 2023-2024 | Myfembree, Gemtesa |
| Roche Diagnostics Corporation | $45.59 | 2019 | |
| Sage Therapeutics, LLC | $37.36 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $26.29 | 2019-2020 | |
| Minerva Surgical, INC | $26.19 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.52 | 2019-2021 | |
| Kci USA, INC. | $16.05 | 2023 | Prevena |
| Smith+Nephew, INC. | $13.84 | 2022 | |
| Radius Health, INC. | $13.70 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.90 | 2019 | |
| Myovant Sciences INC. | $12.63 | 2022 | |
| Avion Pharmaceuticals | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.